Bharat Biotech

Global Red Biotechnology Market to 2030: Declining Prices of DNA Sequencing Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 31, 2023

Robust pipeline is also expected to propel the growth of red biotechnology market on account of number of expected regulatory approvals in coming years.

Key Points: 
  • Robust pipeline is also expected to propel the growth of red biotechnology market on account of number of expected regulatory approvals in coming years.
  • COVID- 19 pandemic also had a positive impact on the global market.
  • By product, the monoclonal antibody is considered to be a relatively more mature and dominant segment compared to other products in the red biotechnology market.
  • By end-user, the pharmaceutical & biotechnology companies accounted for majority of revenue in the red biotechnology industry.

The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar

Retrieved on: 
Wednesday, February 15, 2023

SYDNEY, AU, Feb 15, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.

Key Points: 
  • SYDNEY, AU, Feb 15, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.
  • https://novotech-cro.com/whitepapers/vaccines-asia-pacific-clinical-tria...
    The webinar, Keeping pace with the evolving global landscape in vaccine development, will hear from a panel of life science experts on the latest advancements and innovative modalities paving the way in the global vaccine development space including:
    - The COVID-19 impact on drug development and the regulatory landscape.
  • - Key factors contributing to Asia Pacific being recognised as the hub for vaccine development and opportunities for biotech's to leverage.
  • - Key considerations for pre-clinical and clinical planning to accelerate vaccine development, supporting a robust global strategy.

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met

Retrieved on: 
Monday, January 9, 2023

“The successful completion of this study represents an important milestone to the ongoing management of COVID-19,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.

Key Points: 
  • “The successful completion of this study represents an important milestone to the ongoing management of COVID-19,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.
  • Blinded safety results and preliminary unblinded immunogenicity results are available through Day 56, one month following the second vaccination.
  • Approximately 24% of tested participants in the U.S. were vaccine-naïve while all participants in the Bharat Biotech Phase 3 study were vaccine-naïve.
  • There were no deaths, related potential immune mediated medical conditions (PIMMCs), or related adverse events of special interest (AESIs).

Nasal Vaccines Global Markets and Pipeline Analysis Research Report 2022 - Trends and Sales Forecasts through 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023

The "Nasal Vaccines: Global Markets and Pipeline Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nasal Vaccines: Global Markets and Pipeline Analysis" report has been added to ResearchAndMarkets.com's offering.
  • This report examines trends and sales in the global market for nasal vaccines through 2027.
  • Nasal vaccines achieve both: They eliminate the use of needles, thus reducing the cost of vaccines and facilitating mass vaccination.
  • The report examines all forms of nasal vaccines, such as nasal drops or sprays, but excludes intramuscular and oral vaccines.

Pediatric Vaccines Global Markets Report 2022: Impacts of COVID-19, Market Revenue Data for 2020 and 2021, Estimates for 2022, and CAGR Projections through 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022

This report highlights the current and future market potential of pediatric vaccines and a detailed analysis of the market's drivers, challenges and opportunities.

Key Points: 
  • This report highlights the current and future market potential of pediatric vaccines and a detailed analysis of the market's drivers, challenges and opportunities.
  • The report also covers market projections through 2027 and estimates market shares for key players, as well as pediatric vaccines by type and by application.
  • The report also discusses the impact of the COVID-19 pandemic on this market.
  • Vaccines are one of the most significant advances in global health and are the most cost-effective strategy to reduce child mortality.

Global Vaccine Market Breaks $200 Billion, Up from $128 Billion in 2021

Retrieved on: 
Monday, November 7, 2022

ARLINGTON, Va. , Nov. 7, 2022  /PRNewswire-PRWeb/ -- In 2022, the global market for vaccines is estimated to reach $202.6 billion. COVID-19 vaccines represent roughly two-thirds of these revenues, according to a recent market research report The 2022 World Market for Vaccines published by Kalorama Information, a leading medical market research firm.

Key Points: 
  • ARLINGTON, Va., Nov. 7, 2022 /PRNewswire-PRWeb/ -- In 2022, the global market for vaccines is estimated to reach $202.6 billion.
  • COVID-19 vaccines represent roughly two-thirds of these revenues, according to a recent market research report The 2022 World Market for Vaccines published by Kalorama Information, a leading medical market research firm.
  • Sales increased from $127.6 billion in 2021 to an estimated $202.6 billion in 2022.
  • Companies that compete in the vaccine market include Astra Zeneca, Pfizer, Moderna and Glaxo CSL, Johnson and Johnson, Dynavax, Inovio, Novavax, Merck & Co, Inc., Sanofi Pasteur, Bharat Biotech, and Takeda, among others.

Malaria Vaccines Global Market Report 2022: Featuring GlaxoSmithKline, BioNTech, VLP Therapeutics & More - ResearchAndMarkets.com

Retrieved on: 
Friday, October 21, 2022

Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes.

Key Points: 
  • Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes.
  • Malaria vaccines are used to prevent the spread of malaria.
  • Key players operating in the global malaria vaccine market are focusing on adoption of growth strategies such as agreements which are expected to drive market growth during the forecast period.
  • Moreover, increasing research and development for malaria vaccine is expected to propel the global malaria vaccine market over the forecast period.

Global Vaccine Market Exceeds $200 Billion: Kalorama Information Report

Retrieved on: 
Thursday, October 6, 2022

ARLINGTON, Va., Oct. 6, 2022 /PRNewswire-PRWeb/ -- In 2022, the global market for vaccines is estimated to reach $202.6 billion. COVID-19 vaccines represent roughly two thirds of these revenues, according to Kalorama Information's just-published market research report "The 2022 World Market for Vaccines".

Key Points: 
  • ARLINGTON, Va., Oct. 6, 2022 /PRNewswire-PRWeb/ -- In 2022, the global market for vaccines is estimated to reach $202.6 billion.
  • COVID-19 vaccines represent roughly two thirds of these revenues, according to Kalorama Information's just-published market research report " The 2022 World Market for Vaccines ".
  • Kalorama's report estimates total sales earned by vaccine manufacturers such as Astra Zeneca, Pfizer, Moderna and Glaxo and others, and projects revenues in various vaccine product segments to 2027.
  • Companies use the Kalorama reports to benchmark market share, and investors and investment firms use reports to assess companies.

Middle East and Africa Travel Vaccines Market Analysis/Forecast Report 2022-2028 Featuring Abbott, Bharat Biotech, GlaxoSmithKline, Merck & Co, Novartis, Pfizer, & Sanofi - ResearchAndMarkets.com

Retrieved on: 
Monday, September 26, 2022

Continuous demand for life-saving vaccines is the major factor leading to the growth of the travel vaccines market in the region.

Key Points: 
  • Continuous demand for life-saving vaccines is the major factor leading to the growth of the travel vaccines market in the region.
  • The MEA travel vaccines market, based on product, is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others.
  • The MEA travel vaccines market, based on application, is segmented into domestic travel and outbound travel.
  • Based on country, the MEA travel vaccines market is segmented into Saudi Arabia, South Africa, UAE, and the Rest of the MEA.

Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology

Retrieved on: 
Wednesday, September 14, 2022

BBV152, commercialized as COVAXIN, is developed and manufactured by Ocugens partner Bharat Biotech , a global leader in vaccine innovation based in Hyderabad, India.

Key Points: 
  • BBV152, commercialized as COVAXIN, is developed and manufactured by Ocugens partner Bharat Biotech , a global leader in vaccine innovation based in Hyderabad, India.
  • BBV152 is currently authorized by the World Health Organization, authorized under Emergency Use Authorization in 28 countries, and accepted as a COVID-19 vaccine to travel into over 85 countries.
  • It is under clinical investigation by Ocugen in the United States for use in adults aged 18 years and older.
  • Additionally, BBV152 has a broader impact on public health, as it induces high neutralization efficacy against different SARS-CoV-2 variants of concern.